2.18
price up icon8.46%   0.17
after-market Dopo l'orario di chiusura: 2.21 0.03 +1.38%
loading

Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie

pulisher
Nov 19, 2024

Recent Analysts’ Ratings Updates for Taysha Gene Therapies (TSHA) - Defense World

Nov 19, 2024
pulisher
Nov 19, 2024

Canaccord Genuity Group Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World

Nov 19, 2024
pulisher
Nov 15, 2024

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Expert Outlook: Taysha Gene Therapies Through The Eyes Of 7 Analysts - Benzinga

Nov 15, 2024
pulisher
Nov 15, 2024

Taysha Gene Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 15, 2024

RA Capital Management, L.P. Increases Stake in Taysha Gene Thera - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap DownHere's Why - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Hims & Hers stock falls as Amazon launches Telehealth offering - MSN

Nov 14, 2024
pulisher
Nov 14, 2024

Avoro Capital Advisors LLC Increases Stake in Taysha Gene Therap - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga

Nov 14, 2024
pulisher
Nov 14, 2024

Creative Planning Makes New $28,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Nov 14, 2024
pulisher
Nov 14, 2024

Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlight - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ... - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Taysha Gene Therapies Advances in Rett Syndrome Trials - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Taysha Gene Therapies reports on TSHA-102 Rett Syndrome trial By Investing.com - Investing.com South Africa

Nov 13, 2024
pulisher
Nov 13, 2024

Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

Taysha Gene Reports Strong Safety Data, FDA Approval for TSHA-102 Trials; Net Loss Narrows | TSHA Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Taysha Gene Therapies' SWOT analysis: promising Rett syndrome stock faces pivotal year - Investing.com UK

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC's Strategic Reduction in Taysha Gene Therapies Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Neurogene’s Rett Data Draw Optimism Despite Serious Adverse Event - Citeline News & Insights

Nov 12, 2024
pulisher
Nov 12, 2024

Preview: Taysha Gene Therapies's Earnings - Benzinga

Nov 12, 2024
pulisher
Nov 12, 2024

JMP Securities Reaffirms "Market Outperform" Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Piper Sandler expects Taysha Gene to recover, maintains $7 shares target - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

U.S. Stock market top gainers: BTC Digital surges by 68.60%, Revance Therapeutics climbed by 20.00% in early trading - Business Upturn

Nov 12, 2024
pulisher
Nov 12, 2024

Piper Sandler stays bullish on Taysha Gene shares, maintains Overweight rating - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

Taysha Gene Therapies' (TSHA) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Taysha Gene Therapies' (TSHA) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Analyzing Taysha Gene Therapies (NASDAQ:TSHA) & Gilead Sciences (NASDAQ:GILD) - Defense World

Nov 12, 2024
pulisher
Nov 11, 2024

Neurogene plummets 35% on gene therapy trial data for Rett syndrome - Seeking Alpha

Nov 11, 2024
pulisher
Nov 11, 2024

Taysha Gene Therapies Inc (NASDAQ: TSHA) Gains 5.63% In Early Trade; What Lies Ahead? - Stocks Register

Nov 11, 2024
pulisher
Nov 09, 2024

Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.38 - Defense World

Nov 09, 2024
pulisher
Nov 07, 2024

Taysha Gene Therapies (TSHA) to Release Earnings on Wednesday - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13 - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Taysha Gene Therapies to Release Third Quarter 2024 - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Taysha Gene Therapies reiterates stock target with positive outlook By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 01, 2024

TSHATaysha Gene Therapies, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024
pulisher
Oct 29, 2024

ABEOAbeona Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Oct 29, 2024
pulisher
Oct 26, 2024

SG Americas Securities LLC Purchases Shares of 63,984 Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Oct 26, 2024
pulisher
Oct 24, 2024

Taysha Gene Therapies' SWOT analysis: promising gene therapy stock faces key catalysts - Investing.com

Oct 24, 2024
pulisher
Oct 22, 2024

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress - The Manila Times

Oct 22, 2024
pulisher
Oct 22, 2024

Taysha Gene Therapies to Present Biodistribution Data from - GlobeNewswire

Oct 22, 2024
pulisher
Oct 22, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire

Oct 22, 2024
pulisher
Oct 16, 2024

Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds? - Insider Monkey

Oct 16, 2024
pulisher
Oct 15, 2024

Trading Day Review: Taysha Gene Therapies Inc (TSHA) Loses Momentum, Closing at 1.99 - The Dwinnex

Oct 15, 2024
pulisher
Oct 15, 2024

Can you now get a good deal on Taysha Gene Therapies Inc’s shares? - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

Benitec Biopharma’s Oculopharyngeal Muscular Dystrophy Gene Therapy Produces Clinical Improvements in Swallowing in Phase 1b/2a Trial - CGTLive™

Oct 15, 2024
pulisher
Oct 15, 2024

When a Miracle Cure Is Left on the Shelf - Bloomberg

Oct 15, 2024
pulisher
Oct 14, 2024

Investing in Taysha Gene Therapies Inc (TSHA): What You Must Know - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why - Yahoo Finance

Oct 14, 2024
pulisher
Oct 14, 2024

Taysha Gene Therapies Inc (TSHA) is looking forward to a strong quarter - SETE News

Oct 14, 2024
pulisher
Oct 14, 2024

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Position Lowered by Renaissance Technologies LLC - MarketBeat

Oct 14, 2024
pulisher
Oct 14, 2024

Taysha Gene Therapies: Unjustified Sell-OffEnough Cash Runway And Promising Rett Syndrome Data - Seeking Alpha

Oct 14, 2024
pulisher
Oct 12, 2024

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Brokerages - MarketBeat

Oct 12, 2024
pulisher
Oct 10, 2024

TSHA Stock Sees Decline of Approximately -2.44% in Last Five Days - Knox Daily

Oct 10, 2024
pulisher
Oct 10, 2024

The Significance of Moving Averages in Taysha Gene Therapies Inc Inc. (TSHA) Price Performance - The InvestChronicle

Oct 10, 2024
pulisher
Oct 09, 2024

Are Taysha Gene Therapies Inc’shares a good deal? - US Post News

Oct 09, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
Capitalizzazione:     |  Volume (24 ore):